AbbVie · company speakers →
shared data on ABBV-969, a first-in-class antibody-drug conjugate designed to target two antigens that are often overexpressed in metastatic castration-resistant prostate cancer (mCRPC): prostate-specific membrane antigen (PSMA) and six-transmembrane epithelial antigen of prostate 1 (STEAP1).
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →